Literature DB >> 19291727

Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.

Joshua J Field1, Robert C Strunk, Jessica E Knight-Perry, Morey A Blinder, R Reid Townsend, Michael R DeBaun.   

Abstract

Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P < 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291727     DOI: 10.1002/ajh.21370

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

1.  Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease.

Authors:  Robyn T Cohen; Michael R DeBaun; Morey A Blinder; Robert C Strunk; Joshua J Field
Journal:  Blood       Date:  2010-05-06       Impact factor: 22.113

Review 2.  Asthma morbidity and treatment in children with sickle cell disease.

Authors:  Samuel O Anim; Robert C Strunk; Michael R DeBaun
Journal:  Expert Rev Respir Med       Date:  2011-10       Impact factor: 3.772

Review 3.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

4.  Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice.

Authors:  Kirkwood A Pritchard; Thom R Feroah; Sandhya D Nandedkar; Sandra L Holzhauer; William Hutchins; Marie L Schulte; Robert C Strunk; Michael R Debaun; Cheryl A Hillery
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-27       Impact factor: 6.914

5.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

6.  Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia.

Authors:  Deepika S Darbari; Onyinye Onyekwere; Mehdi Nouraie; Caterina P Minniti; Lori Luchtman-Jones; Sohail Rana; Craig Sable; Gregory Ensing; Niti Dham; Andrew Campbell; Manuel Arteta; Mark T Gladwin; Oswaldo Castro; James G Taylor; Gregory J Kato; Victor Gordeuk
Journal:  J Pediatr       Date:  2011-09-03       Impact factor: 4.406

Review 7.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

8.  Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

Authors:  Joshua J Field; Adetola Kassim; Amanda Brandow; Stephen H Embury; Neil Matsui; Karina Wilkerson; Valencia Bryant; Liyun Zhang; Pippa Simpson; Michael R DeBaun
Journal:  Blood Adv       Date:  2020-03-24

9.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694

10.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.